According to the analysis of the contract, the agreement did not include provisions to illustrate the consequences if the drugmaker failed to deliver on time. Such were the poor provisions to ensure the delivery of the vaccine that consultancy firm, Deloitte warned the Belgium government to sign a separate contract with AstraZeneca. Due to the poor provisions in the contract with the EU, Deloitte urged Belgium to sign a quality agreement with AstraZeneca in order to detail the consequences if the delivery of vaccines were not met.